Tenaya Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 14, 2024. Tenaya is a clinical-stage biotechnology company developing therapies for heart disease. It has no approved products and has generated no revenue.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $25.1 million | $25.6 million; down 2% |
| General and administrative expense | $8.7 million | $8.1 million; up 7% |
| Total operating expenses | $33.8 million | $33.7 million; approximately flat |
| Net loss | $32.2 million | $31.7 million |
| Net loss per share, basic and diluted | $0.40 | $0.43 |
| Net cash used in operating activities | $28.7 million | $30.3 million |
| Cash, cash equivalents and marketable securities | $122.2 million at March 31, 2024 | $104.6 million at December 31, 2023 |
| Total liabilities | $26.7 million | $31.1 million at December 31, 2023 |
Tenaya reported no product revenue, so revenue margins are not meaningful. The company reported no income tax expense. It had $11.4 million in operating lease liabilities; the filing does not report borrowings as debt.
Material changes and financing
- R&D expense declined $0.6 million, primarily due to lower facility and laboratory costs, partly offset by higher personnel costs and outside services, including clinical-trial activity.
- G&A expense rose $0.6 million, primarily due to higher stock-based compensation and professional fees. Interest income fell $0.5 million, mainly reflecting lower cash and investment balances.
- In February 2024, Tenaya completed a follow-on offering of common stock and pre-funded warrants, receiving approximately $46.8 million net. Weighted-average shares increased to 81.0 million from 73.1 million a year earlier; additional share issuance may dilute existing holders.
- At March 31, approximately $71.0 million remained available under the company’s ATM program.
Outlook, programs and risks
- Management expects existing cash, cash equivalents and investments to fund operations for at least 12 months following the filing. It also states that substantial additional funding will be needed to complete development and potentially commercialize candidates; future financing may dilute shareholders or require licensing or collaboration arrangements.
- Management expects operating expenses to remain relatively flat over the next 12 months, with R&D and G&A expenses generally expected to remain flat for the rest of 2024. No specific revenue or earnings guidance is provided.
- TN-201: Phase 1b MyPEAK-1 dosing began in October 2023 for MYBPC3-associated hypertrophic cardiomyopathy; initial trial data are anticipated in the second half of 2024. TN-201 has FDA Fast Track and orphan designations.
- TN-401: The FDA cleared the IND in October 2023 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Tenaya plans to begin dosing in the Phase 1b RIDGE-1 trial in the second half of 2024. TN-401 has FDA Fast Track and orphan designations.
- TN-301: The company reported generally favorable Phase 1 tolerability and pharmacokinetic findings in healthy participants and says it believes late-stage development is best pursued by or with a well-resourced partner.
- On May 14, 2024, after quarter-end, Tenaya announced cost-containment measures including a planned workforce reduction of approximately 22%, prioritizing data generation from its clinical-stage gene therapy programs. It estimates $1.3–$1.5 million in related charges, substantially in Q2 2024; actual costs and savings may differ, and the filing warns of possible operational disruption.
- Key risks include clinical and regulatory uncertainty, gene-therapy safety and manufacturing challenges, patient enrollment, reliance on third parties, competition, intellectual-property disputes, and the need to raise additional capital. The filing notes potential third-party patent rights that could be asserted against TN-201 or certain AAV vectors, while stating Tenaya believes it has defenses.
- No material litigation was reported as of March 31, 2024. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether TN-201 produces the expected initial clinical data in the second half of 2024, and the safety, efficacy and durability of any reported results.
- Whether TN-401 begins patient dosing on the anticipated schedule and whether trial enrollment and progress meet management’s expectations.
- How the 22% workforce reduction affects program execution, operating costs, and the timing and amount of the disclosed severance charges.
- Cash use and remaining runway as clinical programs advance, and the company’s ability to secure additional financing on acceptable terms.
- Potential dilution from outstanding pre-funded warrants, equity awards, and future use of the ATM; the filing reports 22.1 million shares reserved or potentially issuable on an as-if-converted basis at March 31, 2024.
- Developments in potential third-party intellectual-property claims and the feasibility of partnering TN-301.